BeOne Medicines Ltd ADR’s recent filing unveils that its Affiliate Baker Brothers Life Sciences, acquired Company’s shares for reported $174.71 million on Feb 28 ’25. In the deal valued at $260.00 per share,671,976 shares were bought.
Then, 667, L.P. bought 60,851 shares, generating $15,821,260 in total proceeds.
Before that, BAKER BROS. ADVISORS LP sold 732,827 shares. BeOne Medicines Ltd ADR shares valued at $190,535,020 were divested by the Director at a price of $260.00 per share. As a result of the transaction, BAKER BROS. ADVISORS LP now holds 730,642 shares, worth roughly $198.59 million.
A number of analysts have revised their coverage, including JMP Securities’s analysts, who began to cover the stock in mid September with a ‘”a Mkt outperform”‘ rating. Macquarie started covering the stock on September 12, 2023. It rated ONC as “an Outperform”.
Price Performance Review of ONC
On Friday, BeOne Medicines Ltd ADR [NASDAQ:ONC] saw its stock fall -2.36% to $271.80. Over the last five days, the stock has gained 6.43%. BeOne Medicines Ltd ADR shares have risen nearly 47.15% since the year began. Nevertheless, the stocks have risen 51.26% over the past one year. While a 52-week high of $287.88 was reached on 02/27/25, a 52-week low of $126.97 was recorded on 01/08/25. SMA at 50 days reached $212.38, while 200 days put it at $192.24.
Levels Of Support And Resistance For ONC Stock
The 24-hour chart illustrates a support level at 264.32, which if violated will result in even more drops to 256.84. On the upside, there is a resistance level at 280.23. A further resistance level may holdings at 288.65. The Relative Strength Index (RSI) on the 14-day chart is 78.22, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 25.28, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 23.18%. Stochastics %K at 81.40% indicates the stock is a selling.
The most recent change occurred on August 17, 2023 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $287 price target.
